Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: Comparison with serum levels of sialic acid, TPS and Cyfra 21-1

Cancer Investigation

Volumn 26, Issue 4, 2008, Pages 407-418

  De Castro, Javier ^a   Rodríguez, Marina C ^a   Martínez Zorzano, Vicenta S ^b   Hernández Hernández, Ángel ^c   Llanillo, Marcial ^c   Sánchez Yagüe, Jesús ^c  

^a Unidad de Mama Hospital de la Santísima Trinidad   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cytokeratins; Erythrocyte; Fatty acids; Non small cell lung cancer; Platelet; Sialic acids; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; FATTY ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; SIALIC ACID; SPHINGOMYELIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ERYTHROCYTE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ERYTHROCYTES; FATTY ACIDS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NEOPLASM PROTEINS; PEPTIDES; PHOSPHOLIPIDS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 42649122977     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701788114     Document Type: Article

References (43)

1. Yogeeswaran, G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983, 38, 289-350.
2. Schauer, R. Sialic acid as antigenic determinants of complex carbohydrates. Adv Exp Med Biol 1988, 228, 47-72.
3. Narayanan, S. Sialic acid as a tumor marker. Ann Clin Lab Sci 1994, 24 (4), 376-384.
4. Patel, P.S.; Baxi, B.R.; Balar, D.B. Significance of serum sialoglycoproteins in patients with lung cancer. Neoplasma 1989, 36 (1), 53-59.
5. Stringou, E.; Chondros, K.; Kouvaris, J.; Kakari, S.; Papavassiliou, K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. Anticancer Res 1992, 12 (1), 251-256.
6. Patel, P.S.; Raval, G.N.; Rawal, R.M.; Patel, G.H.; Balar, D.B.; Shah P.M.; Patel, D.D. Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer. Neoplasma 1995, 42 (15), 271-274.
7. Moll, R.; Franke, W.W.; Schiller, D.L.; Geiger, B.; Krepler, R. The catalog of human cytokeratins: patterns of expression in normal ephitelia, tumors and cultured cells. Cell 1982, 31 (1), 11-24.
8. Buccheri, G.; Ferrigno, D. Cytokeratin-derived markers of lung cancer. Expert Rev Mol Diagn 2001, 1 (3) , 315-322.
9. Chen, M.; Hofestadt, R. A medical bioinformatics approach for metabolics disorders. Biomedical data prediction, modelling, and systematic analysis. J Biomed Inform 2006, 39 (2), 147-159.
10. Mosconi, C.; Agradi, E.; Gambetta, A.;. Bozzetti, F.; Galli, C. Decrease of polyunsaturated fatty acids and elevation of the oleic/stearic acid ratio in plasma and red blood cell lipids of malnourished cancer patients. JPEN J Parenter Enteral Nutr 1989, 13 (5), 501-504.
11. Newcomer, L.M.; King, I.B.; Wicklund, K.G.; Stanford, J.L. The association of fatty acids with prostate cancer risk. Prostate 2001, 47 (4), 262-268.
12. Pala, V.; Krogh, V.; Muti, P.; Chajes, V.; Riboli, E.; Micheli, A.; Saadatian, M.; Sieri, S.; Berrino, F. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 2001, 93 (14), 1088-1095.
13. Mikirova, N.; Riordan, H.D.; Jackson, J.A.; Wong, K.; Miranda-Massari, J.R.; Gonzalez, M.J. Erythrocyte membrane fatty acid composition in cancer patients. P R Health Sci J 2004, 23 (2), 107-113.
14. Yi, L.Z.; He, J.; Liang, Y.Z.; Yuan D.L.; Chau, F.T. Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett 2006, 580 (30), 6837-6845.
15. de Castro, J.; Hernández-Hernández, A.; Rodríguez, M.C.; Llanillo, M.; Sánchez-Yagüe, J. Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanzed non-small cell lung cancer. Cancer Invest 2006, 24 (4), 339-345.
16. Zieba, M.; Suwalski, M.; Kwiatkowska, S.; Piasecka, G.; Grzelewska-Rzymowska, I.; Stolarek, R.; Nowak, D. Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir Med 2000, 94 (8), 800-805.
17. Kinnula, V.L.; Paakko, P.; Soini, Y. Antioxidant enzymes and redox-regulating thiol proteins in malignancies of human lung. FEBS Lett 2004, 569 (1-3), 1-6.
18. Hernandez-Hernandez, A.; Llanillo, M.; Rodriguez, M.C.; Gomez, F.; Sanchez-Yague, J. Amphiphilic and hydrophilic nature of sheep and human platelet phosphotyrosine phosphatase forms. Biochim. Biophys Acta 1999, 1419 (2), 195-206.
19. Hernandez-Hernandez, A.; Garabatos, M.N.; Rodríguez, M.C.; Vidal, M.L.; López-Revuelta, A.; Sánchez-Gallego, J.I.; Llanillo, M.; Sanchez-Yagüe, J. Structural characteristics of a lipid peroxidation product, trans-2-nonenal, that favour inhibition of membraneassociated phosphotyrosine phosphatase activity. Biochim Biophys Acta 2005, 1726 (3), 317-325.
20. Warren, L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959, 234 (8), 1971-1975.
21. Aminoff, D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 1961, 81 (Nov), 384-392.
22. Gornall, A.G.; Bardawill, C.J.; David, M.M. Determination of serum proteins by means of Biuret reaction. J Biol Chem 1949, 177 (2), 751-766.
23. López-Revuelta, A.; Sánchez-Gallego, J.I.; Hernández-Hernández, A.; Sánchez-Yagüe, J.; Llanillo, M. Membrane cholesterol contents influence the protective effects of quercetin and rutin in erythrocytes damaged by oxidative stress. Chem Biol Interact 2006, 161 (1), 79-91.
24. López-Revuelta, A.; Sánchez-Gallego, J.I.; Hernández-Hernández, A.; Sánchez-Yagüe, J.; Llanillo, M. Increase in vulnerability to oxidative damage in cholesterol-modified erythrocytes exposed to t-BuOOH. Biochim Biophys Acta 2005, 1734 (1), 74-85.
25. de Castro, J.; Hernández-Hernández, A.; Rodríguez, M.C.; Sardina, J.L.; Llanillo, M.; Sánchez-Yagüe, J. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 2007, 18 (1), 43-51.
26. Kaplan K.L.; Owen, J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981, 57 (2), 199-202.
27. Buccheri, G.; Ferrigno, D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 2001, 34 (Suppl. 2), S65-S69.
28. Fischer, J.R.; Lahm, H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 2004, 45 (Suppl. 2), S151-S161.
29. Plabani, M.; Basso, D.; Navaglia, F.; De Paoli, M.; Tommasini, A.; Cipriani, A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improbe the results?. Br J Cancer 1995, 72 (1), 170-173.
30. Pujol, J.L; Grenier, J.; Parrat, E.; Lehmann, M.; Lafontaine, T.; Quantin X.; Michel, F.B. Cytoqueratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am J Respir Crit Care Med 1996, 154 (3 Pt1), 725-733.
31. Alatas, F.; Alatas, Ö.; Metintas, M.; Colak, Ö.; Harmanci, E.; Demir, S. Diagnostic value of CEA, CA 15-3, CA 19-9, Cygra 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001, 31 (1), 9-16.
32. Kakari, S.; Stringou, E.; Toumbis, M.; Ferderigos, A.S.; Poulaki, I.; Chondros, K.; Dema, A.; Kotsovoulou, V.; Pavlidis, N. Five tumor markers in lung cancer:significance of total and "lipid"-bound sialic acid. Anticancer Res 1991, 11 (6), 2107-2110.
33. Plucinsky, M.C.; Riley, W.M.; Prorok, J.J.; Alhadeff, J.A. Total and lipid associated serum sialic acid levels in cancer patients with different primary sites and different degree of metastatic involvement. Cancer 1986, 58 (12), 2680-2685.
34. Feijoo-Carnero, C.; Rodríguez-Berrocal, F.J.; Páez de la Cadena, M.; Ayude, D.; de Carlos, A. Martínez-Zorzano, V.S. Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence. Int J Biological Markers 2004, 19 (1), 38-45.
35. Straface, E.; Masella, R.; Del Principe, D.; Franceschi, C.; Korkina, L.G.; Zatterale, A.; Pagano, G.; Malorni, W. Spectrin changes occur in erythrocytes from patients with Fanconi's anemia and their parents. Biochem Biophys Res Commun 2000, 273 (3), 899-901.
36. Straface, E.; Matarrese, P.; Gambardella, L.; Forte, S.; Carlone, S.; Libianchi, E.; Schmid, G.; Malorni, W. N-acetylcisteine counteracts erythrocyte alterations occurring in chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2000, 279 (2), 552-556.
37. Straface, E.; Rivabene, R.; Masella, R.; Santulli, M.; Paganelli, R.; Malorni, W. Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes. Protective effects of N-acetylcysteine. Biochem Biophys Res Commun 2002, 290 (5), 1393-1398.
38. Hernández-Hernández, A.; Rodríguez, M.C.; López-Revuelta. A.; Sánchez-Gallego, J.I.; Shnyrov, V.; Llanillo, M.; Sánchez-Yagüe, J. Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cell Mol Dis 2006, 36 (3), 355-363.
39. Khyshiktuev, B.S.; Khyshiktueva, N.A.; Ivanov, V.N.; Darenskaia, S.D.; Novikov, S.V. Fatty acid composition of blood plasma lipids and erythrocytes in lung cancer patients. Vopr Med Khim 1994, 40 (5), 48-50.
40. Prisco, D.; Paniccia, R.; Coppo, M.; Filippini, M.; Francalanci, I.; Brunelli, T.; Comeglio, P.; Abbate, R. Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukot Essent Fatty Acids 1995, 53 (1), 65-68.
41. Prisco, D.; Rogasi, P.G.; Paniccia, R.; Abbate, R.; Gensini, G.F.; Pinto, S.; Vanni D.; Neri-Serneri, G.G. Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. Prostaglandins Leukot Essent Fatty Acids 1989, 35 (1), 15-23.
42. Nakamura, M.T.; Nara, T.Y. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004, 24, 345-376.
43. Kinnula, V.L.; Paakko, P.; Soini, Y. Antioxidant enzymes and redox-regulating thiol proteins in malignancies of human lung. FEBS Lett 2004, 569 (1-3), 1-6.